Compare Apollo Global Management Ord Shs (APO) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Apollo Global Management Ord Shs vs Heron Therapeutics Inc — how do they compare? Apollo Global Management Ord Shs trades at $120 (market cap $69.38B), while Heron Therapeutics Inc trades at $0.42 (market cap $79.52M). The key difference: Apollo Global Management Ord Shs is far larger — about 872.5× Heron Therapeutics Inc's market cap, and Apollo Global Management Ord Shs pays a 1.87% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| APO | HRTX | |
|---|---|---|
Market Cap | $69.38B | $79.52M |
Sector | Financials | Health |
52-Week High | $156.05 | $2.18 |
52-Week Low | $100.30 | $0.39 |
Enterprise Value | -$168.19B | $177.42M |
Dividend Yield | 1.87% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Apollo Global Management (APO) trades at $120.34, up 0.42% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported Q1 2026 EPS of $1.94, beating estimates, and maintains strong analyst support with 23 buy ratings. Recent news highlights private credit growth opportunities alongside liquidity concerns in Apollo's funds.
APO's outlook is supported by earnings beats and a $149.86 consensus price target, but risks include private credit liquidity pressures and a high P/E ratio of 75.69. Investor sentiment is mixed due to ongoing fund withdrawal caps and legal investigations, though long-term growth in alternative assets remains a positive catalyst.
HRTX trades at $0.4144, down 3.29% today, with a bearish technical signal from moving averages. The company reported Q1 2026 revenue of $154.9M with a net loss of $20.2M, missing EPS expectations. Despite negative profitability metrics, analyst sentiment remains overwhelmingly positive with 94.7% buy ratings. Recent news highlights patent litigation developments and management's reaffirmed full-year guidance despite seasonal headwinds.
The stock faces fundamental challenges with negative earnings and cash flow, but strong analyst support and patent protection for key products provide potential upside. Key risks include ongoing operational losses and competitive pressures in the biotechnology sector. The current valuation at 0.46 P/S suggests potential if the company can achieve profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Apollo Global Management Ord Shs
Apollo Global Management Inc is an alternative investment manager. It serves various sectors such as chemicals, manufacturing and industrial, natural resources, consumer and retail, consumer services, business services, financial services, leisure, and media and telecom and technology. The company operates in three business segments that are Private Equity, Credit, and Real Assets. It generates maximum revenue from the Credit segment in the form of fees. The credit segment primarily invests in non-control corporate and structured debt instruments including performing, stressed and distressed instruments across the capital structure. It also includes Corporate Credit
Read more on APO →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
